During the stable phase, it is particularly important to teach the patient and family to recognize prodromal symptoms or early signs of exacerbation. During prodromal episodes, early intervention ...

Late-onset schizophrenia is relatively rare. Further history may reveal prodromal symptoms that mimic ... as well as bipolar disorder, manic phase.

MMI is a clinical entity that is non-specific but may be prodromal to ALS; it emerged from the study ... Such a study could shed light on the presymptomatic phase of both genetic and non-genetic forms ...

Neurocrine Biosciences has commenced a Phase III registrational programme to assess investigational oral muscarinic M4 selective orthosteric agonist NBI-1117568 as a treatment for schizophrenia in ...

has completed enrollment for its Phase 2 clinical trial evaluating ANAVEX3-71 as a treatment for schizophrenia. The study, designated ANAVEX3-71-SZ-001, enrolled 71 participants—16 in the ...

In September 2024, the FDA approved Cobenfy, an oral medication for schizophrenia in adults. Data from the EMERGENT clinical program supported the FDA approval of Cobenfy. In Phase 3 EMERGENT-2 ...

Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in August 2024. "There is a significant need for new and innovative medicines to treat ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative ...